Goldman Sachs’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Goldman Sachs’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,400	Closed	-$364K	–	6461
2020 Q4	$364K	Buy	+8,400	New	+$414K	﹤0.01%	4790
2020 Q2	–	Sell	-27,000	Closed	-$1.38M	–	5580
2020 Q1	$1.38M	Buy	27,000 +22,000	+440%	+$1.47M	﹤0.01%	3543
2019 Q4	$397K	Buy	+5,000	New	+$296K	﹤0.01%	4629
2019 Q3	–	Sell	-30,500	Closed	-$1.6M	–	5459
2019 Q2	$1.6M	Buy	+30,500	New	+$1.75M	﹤0.01%	3675
2018 Q3	–	Sell	-38,500	Closed	-$1.74M	–	5867
2018 Q2	$1.74M	Buy	38,500 +18,500	+93%	+$842K	﹤0.01%	3710
2018 Q1	$966K	Buy	+20,000	New	+$1.12M	﹤0.01%	4070
2017 Q4	–	Sell	-26,000	Closed	-$807K	–	6756
2017 Q3	$807K	Buy	+26,000	New	+$731K	﹤0.01%	4755

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's GBT Position: Q4 2022 in Review

Goldman Sachs sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,706,600 shares — an estimated $116M sold.

Goldman Sachs first reported a position in GBT in Q3 2015 and held it in 28 quarters. The position peaked at $116M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Goldman Sachs reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 1,706,600 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $116M.
Goldman Sachs first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 28 quarters.
Goldman Sachs's Global Blood Therapeutics, Inc. position peaked at $116M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.